menu
    • menu
    [{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BNC375","moa":"Nicotinic alpha-7 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Liquid Suspension","sponsorNew":"Bionomics \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Bionomics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Bionomics \/ Apeiron","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Apeiron"},{"orgOrder":0,"company":"Bionomics","sponsor":"Bionomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Liquid Suspension","sponsorNew":"Bionomics \/ Bionomics","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics \/ Bionomics"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Liquid suspension","sponsorNew":"Bionomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Undisclosed"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Aegis Capital Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"BNC210","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Aegis Capital Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Aegis Capital Corp."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BNC210","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BNC210","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BNC210","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Donepepzil","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Bionomics","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Bionomics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Bionomics \/ Merck & Co"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BNC210","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BNC210","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BNC210","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Not Applicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"BNC210","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Bionomics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics \/ Leerink Partners"},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BNC210","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Bionomics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bionomics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Bionomics

    Menu

    Bionomics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bionomics Initiates Phase 3 AFFIRM-1 Trial with BNC210 for Social Anxiety Disorder

                            Details : BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, which is being evaluated for the treatment of Social Anxiety Disorder.

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 18, 2024

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Leerink Partners

                            Deal Size : $70.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Bionomics Limited Announces Private Placement of up to $70.0 Million

                            Details : The net proceeds will be used to advance the clinical development of BNC210, Aplha-7 receptor NAM. Currently, it is being evlauted for the treatment of social anxiety disorder.

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 31, 2024

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Leerink Partners

                            Deal Size : $70.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bionomics Reports Full Analysis from ATTUNE Phase 2b Trial of BNC210 in PTSD Patients

                            Details : BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, which is being evaluated for the treatment of PTSD and Social Anxiety Disorder.

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 21, 2024

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Regist...

                            Details : BNC210 is a negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor under development for the treatment of social anxiety disorder and post-traumatic stress disorder.

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 16, 2023

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients wit...

                            Details : BNC210 is a negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder.

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2023

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MK-4334,Donepepzil

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $526.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (...

                            Details : Under the collaboration, MK-4334, a novel clinical candidate was developed by MSD and derived from Bionomics’ original α7 nAChR PAM candidate (BNC375) for the treatment of cognitive disorders like Alzheimer’s Disease.

                            Brand Name : MK-4334

                            Molecule Type : Small molecule

                            Upfront Cash : $20.0 million

                            September 14, 2023

                            Lead Product(s) : MK-4334,Donepepzil

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $526.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (P...

                            Details : BNC210 is a negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder.

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 23, 2023

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with ...

                            Details : BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder.

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 27, 2023

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder

                            Details : BNC210 has a novel mechanism of action that involves negative allosteric modulation of the α7 nicotinic acetylcholine receptor. The Company is continuing analysis of the PREVAIL dataset and is assessing next steps for the development of BNC210 in SAD.

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 19, 2022

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bionomics

                            Australia arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Aegis Capital Corp.

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the...

                            Details : BNC210 is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (PTSD).

                            Brand Name : BNC210

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 21, 2022

                            Lead Product(s) : BNC210

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Aegis Capital Corp.

                            Deal Size : $5.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth